webleads-tracker

Transparency

septembre, 2018

  • 26 septembre

    Médicament : un rapport pour améliorer l’information

    Pharma Compliance Info Médicament : un rapport pour améliorer l’information Loi Bertrand

    Le rapport de la « mission information et médicament » mise en place fin 2017 et présidée par Magali LEO (responsable du plaidoyer de l’Association Renaloo) et le Dr Gérald KIERZEK (praticien hospitalier et chroniqueur santé) a été remis lundi 3 septembre 2018 à Agnès Buzyn, la ministre des Solidarités et de la Santé. Ce document formule plusieurs recommandations pour rétablir la confiance, notamment “Un effort accru de transparence” : Réclamant “un effort accru de transparence” à toutes les étapes de vie du médicament, “le rapport propose de “faciliter l’accès aux données et documents scientifiques et économiques à l’origine des …

  • 26 septembre

    Matinale 04/10/2018 | ORDONNANCE TOURAINE : QUEL IMPACT POUR VOS ACTIVITÉS DE TRANSPARENCE ?

    Pharma Compliance Info Matinale 04/10/2018 | ORDONNANCE TOURAINE : QUEL IMPACT POUR VOS ACTIVITÉS DE TRANSPARENCE ? Loi Bertrand

    L’ordonnance du 19 janvier 2017 relative au dispositif anti-cadeaux vient renforcer les dispositions de la Loi Bertrand. Outre l’élargissement à l’ensemble des Industriels des produits de santé, remboursés ou pas, et des catégories de bénéficiaires concernées, elle précise la notion d’avantages et liste les dérogations dont l’admission est conditionnée à la conclusion d’une convention qui doit être déclarée ou autorisée selon les cas. La notion de « prestations de santé » et les modalités d’application de ces dispositions seront définies par un décret en Conseil d’Etat, en cours d’élaboration, qui doit comprendre notamment : – les procédures de déclaration et d’autorisation – l’autorité compétente chargée …

  • 24 septembre

    Senate Expected to Vote on Opioid Legislation includes Expansion of Open Payments to NP’s and PA’s

    Pharma Compliance Info Senate Expected to Vote on Opioid Legislation includes Expansion of Open Payments to NP’s and PA’s US Sunshine Act

    Last Thursday, Senate leaders announced that they had reached an agreement to bring a package of bills to address the nation’s opioid crisis to the Senate floor in the coming days. Among the 70+ provisions is the “Fighting the Opioid Epidemic with Sunshine Provision from Senators Grassley and Blumenthal which Enhances the CMS-run Open Payments, or “sunshine”, program by expanding the types of professionals for whom a drug and device manufacturer is required to report when the manufacturer provides something of value to include: physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives. To read the …

  • 24 septembre

    Top Official at Memorial Sloan Kettering Resigns After Failing to Disclose Industry Ties

    Pharma Compliance Info Top Official at Memorial Sloan Kettering Resigns After Failing to Disclose Industry Ties US Sunshine Act

    Dr. José Baselga, the hospital’s chief medical officer, stepped down days after a report by ProPublica and the New York Times that he failed to disclose millions of dollars in payments from the health care and drug industry in research articles. The revelations about Baselga’s disclosure lapses, reported by The New York Times and ProPublica last weekend, have rocked Memorial Sloan Kettering, one of the nation’s leading cancer centers, in recent days. Its top executives scrambled to contain the fallout, including urgent meetings of physician leaders and the executive committee of its board of directors of drugmaker Bristol-Myers Squibb. To …

juillet, 2018

  • 4 juillet

    Open Payments Data 2017: Significant Drop in Number of Payments

    Pharma Compliance Info Open Payments Data 2017: Significant Drop in Number of Payments US Sunshine Act

    On Friday, June 29, 2018 the Centers for Medicare & Medicaid Services (“CMS”) released the 2017 Open Payments Data, which covers transactions data collected from January 1, 2016 through December 31, 2016. The total dollar amount of payments totaled $8.4 billion (General Payments: $2.82 billion; Research Payments: $4.66 billion; the total records published totaled 11.54 million. The 2017 Open Payments Data shows a 4.7% drop in the total amount of payments from applicable manufacturers and group purchasing organizations (“GPO”) and a 6.9% drop in the total number of payments. To read the article by Thomas Sullivan

  • 4 juillet

    The Patient Advocacy Groups that Accept the Most Big Pharma Money

    Pharma Compliance Info The Patient Advocacy Groups that Accept the Most Big Pharma Money US Sunshine Act

    Eight out of ten patient advocacy groups accept money from drug and medical device companies. Pharmaceutical donations make up more than half of the yearly income of some patient advocacy groups. Are these good natured corporate donations, or just another way that Big Pharma exerts their influence beyond corporate walls? That question isn’t an easy one to answer. But the first step in understanding how large of a role pharmaceutical companies play in organizations like the American Diabetes Association or the American Heart Association is to follow the money. Pharmaceutical donations make up more than half of the yearly income …

X